Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Otorhinolaryngology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 69 articles: HTML format

Single Articles

July 2026
1. FANG Y, Yi C, Sun R, Shen B, et al
   Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer.
   Int J Cancer. 2026 Jul 26. doi: 10.1002/ijc.70675.
   PubMed     Abstract available
   
   
   
2. GAI X, Huang S, Ye J, Zeng J, et al
   Effects of Hippocampal Avoidance on Anxiety in Patients With Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiotherapy: A Single-Center, Single-Arm, Prospective Clinical Trial.
   Int J Cancer. 2026 Jul 26. doi: 10.1002/ijc.70631.
   PubMed     Abstract available
   
   
   
3. XING S, Shi S, Jin M, Han L, et al
   Pembrolizumab-Chemotherapy Versus Pembrolizumab in Head and Neck Squamous Cell Carcinoma: A PD-L1 CPS-Stratified Analysis of Updated KEYNOTE-048 Data.
   Int J Cancer. 2026 Jul 11. doi: 10.1002/ijc.70649.
   PubMed     Abstract available
   
   
   May 2026
4. LIN G, Ge F, Liu Y, Men Y, et al
   Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy.
   Int J Cancer. 2026 May 20. doi: 10.1002/ijc.70521.
   PubMed     Abstract available
   
   
   
5. XIA X, Yan J, Xu L, Sun X, et al
   Nimotuzumab Combined With Concurrent Curative Radiotherapy and S-1 in 75 Years and Older Patients With Stage II-IVB Esophageal Squamous Cell Carcinoma: A Phase II Study.
   Int J Cancer. 2026 May 13. doi: 10.1002/ijc.70550.
   PubMed     Abstract available
   
   
   
6. HUANG S, Han YQ, Yang KY, Qu S, et al
   Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Multicenter Phase 2 Study.
   Int J Cancer. 2026 May 7. doi: 10.1002/ijc.70542.
   PubMed     Abstract available
   
   
   April 2026
7. DE ABREU M, Kowalski LP, Lopez RM, Barul C, et al
   Risk of Head and Neck Cancer in Former Smokers by Subsite: A Multicenter Analysis From the INHANCE Consortium.
   Int J Cancer. 2026 Apr 21. doi: 10.1002/ijc.70497.
   PubMed     Abstract available
   
   
   
8. MARINHO MFP, da Fonseca Simas KB, Heras PV, da Cruz CAS, et al
   Effectiveness of Organized Strategies to Enhance Access to Preventive Oral Cancer Screening Among High-Risk Individuals in Brazil: A Randomized Clinical Trial in Primary Care.
   Int J Cancer. 2026 Apr 21. doi: 10.1002/ijc.70511.
   PubMed     Abstract available
   
   
   
9. WEGGE M, Dok R, Dubois LJ, Nuyts S, et al
   Hypoxia Induces a Mitotic Survival Advantage After Radiotherapy in Head and Neck Cancer Cells.
   Int J Cancer. 2026 Apr 13. doi: 10.1002/ijc.70479.
   PubMed     Abstract available
   
   
   
10. BEAUSSIRE-TROUVAY L, Obongo-Anga FR, Leveque E, Berghian A, et al
    Peri-Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor-Informed Assay in Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Int J Cancer. 2026 Apr 10. doi: 10.1002/ijc.70478.
    PubMed     Abstract available
    
    
    
11. JAKOBSEN KK, Rehman U, Gronhoj C, Lau ZJ, et al
    Awareness of Human Papillomavirus (HPV), Increasing Rates of Oropharyngeal Cancer, and Estimated Economic Burden in Denmark.
    Int J Cancer. 2026 Apr 7. doi: 10.1002/ijc.70477.
    PubMed     Abstract available
    
    
    March 2026
12. LIU Y, Li B, Wang Z, Zheng S, et al
    Impact of lymphatic ablation approaches on immunotherapy efficacy in advanced/metastatic esophageal squamous cell carcinoma: A multi-institutional retrospective cohort study.
    Int J Cancer. 2026 Mar 23. doi: 10.1002/ijc.70459.
    PubMed     Abstract available
    
    
    
13. LI R, Shayan G, Zhao Y, Zhang S, et al
    Trends and epidemiology of human papillomavirus-related oropharyngeal cancer in Chinese populations from 2010 to 2024.
    Int J Cancer. 2026;158:1564-1576.
    PubMed     Abstract available
    
    
    
14. YAKSICH L, Hartel G, Panizza BJ, Whiteman DC, et al
    Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time.
    Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70432.
    PubMed     Abstract available
    
    
    February 2026
15. NETHAN ST, Perez-de-Oliveira ME, Campbell F, Santos-Silva AR, et al
    Interventions for oral cancer prevention: An evidence and gap map.
    Int J Cancer. 2026 Feb 23. doi: 10.1002/ijc.70391.
    PubMed     Abstract available
    
    
    
16. WU H, Li Y, Ran L, Xia Z, et al
    Needle-shaped diatom frustules in food as a possible promoter of esophageal squamous cell carcinoma in coastal southeastern China: A pilot study.
    Int J Cancer. 2026 Feb 23. doi: 10.1002/ijc.70394.
    PubMed     Abstract available
    
    
    
17. PENG L, Ding X, Zou RC, You R, et al
    Comparison of >/=2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma.
    Int J Cancer. 2026 Feb 23. doi: 10.1002/ijc.70399.
    PubMed     Abstract available
    
    
    
18. CUI Z, Zhao Y, Xu Q, Zhao R, et al
    Multilevel pathways to esophageal cancer: Population attributable risks of modifiable exposures, surrogate blood biomarkers, and genetic susceptibility, and the mediation effects based on a 10-year prospective cohort study.
    Int J Cancer. 2026 Feb 16. doi: 10.1002/ijc.70383.
    PubMed     Abstract available
    
    
    
19. OUYANG YF, Liang JL, Xie RQ, Liu YP, et al
    The value of nasopharyngeal brush versus plasma EBV DNA detection in diagnosing local recurrence of nasopharyngeal carcinoma.
    Int J Cancer. 2026 Feb 3. doi: 10.1002/ijc.70357.
    PubMed     Abstract available
    
    
    December 2025
20. TSEGAYE AT, Mashele SA, Shing JZ, Mwansa-Kambafwile J, et al
    Race-specific temporal trends of HPV-related cancers in South Africa: An analysis of the South African National Cancer Registry, 2011-2022.
    Int J Cancer. 2025 Dec 31. doi: 10.1002/ijc.70323.
    PubMed     Abstract available
    
    
    
21. HADJI M, Rashidian H, Marzban M, Rezaianzadeh A, et al
    The association between waterpipe smoking and head and neck squamous cell carcinoma: A multicenter case-control study in Iran.
    Int J Cancer. 2025 Dec 26. doi: 10.1002/ijc.70258.
    PubMed     Abstract available
    
    
    
22. TAYLOR KJ, Amdal CD, Bjordal K, Astrup GL, et al
    Reply to 'Comment on "Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis"'.
    Int J Cancer. 2025 Dec 18. doi: 10.1002/ijc.70292.
    PubMed    
    
    
    
23. MISRA SR, Das R
    Comments on "Evaluating ChatGPT's recommendations for systematic treatment decisions in recurrent or metastatic head and neck squamous cell carcinoma: Perspectives from experts and junior doctors".
    Int J Cancer. 2025 Dec 17. doi: 10.1002/ijc.70303.
    PubMed    
    
    
    
24. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Comment on "Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis".
    Int J Cancer. 2025 Dec 15. doi: 10.1002/ijc.70290.
    PubMed    
    
    
    November 2025
25. WANG Y, Xi Y, Qiao L, Yu Y, et al
    Ethnic, sex, and age disparities in esophageal cancer and medical costs: A population-based study of 18 million people in China.
    Int J Cancer. 2025 Nov 11. doi: 10.1002/ijc.70236.
    PubMed     Abstract available
    
    
    October 2025
26. JIANG KY, Hu WL, Liu SX, Wang L, et al
    Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study.
    Int J Cancer. 2025 Oct 28. doi: 10.1002/ijc.70214.
    PubMed     Abstract available
    
    
    
27. NASMAN T, Birgersson M, Marklund L, Nasman A, et al
    Spatial evidence for carcinoma in situ (CIS) as an entity in human papillomavirus (HPV)-associated tonsillar squamous cell carcinoma (TSCC).
    Int J Cancer. 2025 Oct 23. doi: 10.1002/ijc.70207.
    PubMed     Abstract available
    
    
    
28. SU Q, Feng R, Du S, Zhao H, et al
    Urinary mycotoxins and esophageal cancer risk in China: A case-cohort study.
    Int J Cancer. 2025 Oct 20. doi: 10.1002/ijc.70206.
    PubMed     Abstract available
    
    
    
29. HAN W, Gao L, Wang X, Li C, et al
    Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial.
    Int J Cancer. 2025 Oct 15. doi: 10.1002/ijc.70176.
    PubMed     Abstract available
    
    
    September 2025
30. VERHOEVEN RHA, Kuijper SC, Slingerland M, Wijnhoven B, et al
    Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real-world matched comparison of overall survival.
    Int J Cancer. 2025 Sep 23. doi: 10.1002/ijc.70168.
    PubMed     Abstract available
    
    
    
31. OSWAL K, Barman S, Kerr AR, Zaman M, et al
    Oral cancer risk stratification: A cross-sectional population-based screening study in Northeast India.
    Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70160.
    PubMed     Abstract available
    
    
    
32. AMURE MT, Madathil SA, Laprise C, Rousseau MC, et al
    Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70124.
    PubMed     Abstract available
    
    
    
33. DENNIS CD, Cohen DJ, Debnath K, Schwartz N, et al
    24R,25(OH)(2)D(3) regulates tumorigenesis in estrogen sensitive laryngeal cancer cells via membrane-associated receptor complexes in ER+ and ER- cells.
    Int J Cancer. 2025 Sep 8. doi: 10.1002/ijc.70141.
    PubMed     Abstract available
    
    
    August 2025
34. NASMAN A, Birgersson M, Nasman T, Jortso E, et al
    Age and tumour presentations differ between HPV type 16 positive and other high-risk HPV type-positive oropharyngeal squamous cell carcinomas in a Swedish cohort of 2000-2022.
    Int J Cancer. 2025 Aug 15. doi: 10.1002/ijc.70087.
    PubMed     Abstract available
    
    
    
35. ZHANG LT, Wu XY, Zhang HY, Li EM, et al
    Exploring solute carriers as biomarkers and therapeutic targets in esophageal squamous cell carcinoma.
    Int J Cancer. 2025 Aug 11. doi: 10.1002/ijc.70080.
    PubMed     Abstract available
    
    
    July 2025
36. TAYLOR KJ, Amdal CD, Bjordal K, Astrup GL, et al
    Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis.
    Int J Cancer. 2025 Jul 30. doi: 10.1002/ijc.70033.
    PubMed     Abstract available
    
    
    
37. YAN D, Wang L, Huang L, Cheng K, et al
    Evaluating ChatGPT's recommendations for systematic treatment decisions in recurrent or metastatic head and neck squamous cell carcinoma: Perspectives from experts and junior doctors.
    Int J Cancer. 2025 Jul 19. doi: 10.1002/ijc.70001.
    PubMed     Abstract available
    
    
    
38. WANG J, Wang L, Wang T, Tang T, et al
    Eye-sparing treatment for sinonasal tumors invading the orbit in the era of personalized therapy.
    Int J Cancer. 2025;157:151-160.
    PubMed     Abstract available
    
    
    June 2025
39. SONG XY, Lin L, Yang Y, Hu HH, et al
    Radiotherapy as an organ-preserving alternative to surgery in patients with locally advanced esophageal squamous cell carcinoma achieving major pathologic response after induction immunochemotherapy.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.35515.
    PubMed     Abstract available
    
    
    
40. MODESTO A, Gibert S, Delmas C, Tougeron D, et al
    Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancer.
    Int J Cancer. 2025 Jun 20. doi: 10.1002/ijc.70011.
    PubMed     Abstract available
    
    
    May 2025
41. LIN H, Ma J, Heng Y, Zhu X, et al
    CD8(+) T cells in patients with hypopharyngeal squamous cell carcinoma are susceptible to radiation-induced damage.
    Int J Cancer. 2025;156:2010-2023.
    PubMed     Abstract available
    
    
    
42. YAN L, Lin Y, Lin W, Hong J, et al
    Treatment outcomes in nasopharyngeal carcinoma patients with parotid lymph node metastasis: An 11-year experience at a tertiary cancer center.
    Int J Cancer. 2025 May 7. doi: 10.1002/ijc.35470.
    PubMed     Abstract available
    
    
    March 2025
43. LAN K, Liu S, Li S, Sun X, et al
    Comparing outcomes and toxicities among patients with nasopharyngeal carcinoma treated with daytime versus evening radiotherapy: A retrospective analysis with propensity score matching.
    Int J Cancer. 2025 Mar 29. doi: 10.1002/ijc.35408.
    PubMed     Abstract available
    
    
    
44. 
    Correction to "Chronotherapy in head and neck cancer: A systematic review and meta-analysis".
    Int J Cancer. 2025 Mar 7. doi: 10.1002/ijc.35396.
    PubMed    
    
    
    February 2025
45. HU Y, Lu T, Zhang H, Chen B, et al
    Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study.
    Int J Cancer. 2025 Feb 24. doi: 10.1002/ijc.35382.
    PubMed     Abstract available
    
    
    
46. WANG H, Fan T, Lu Y, Que L, et al
    Baseline audiometric assessment of newly diagnosed nasopharyngeal carcinoma patients: a multicentre cross-sectional study.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35358.
    PubMed     Abstract available
    
    
    January 2025
47. XIAO Z, Chen W, Du Y, Zeng F, et al
    Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial.
    Int J Cancer. 2025 Jan 18. doi: 10.1002/ijc.35340.
    PubMed     Abstract available
    
    
    December 2024
48. WANG J, Li B, Zhang Y, Luo X, et al
    Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35261.
    PubMed     Abstract available
    
    
    
49. JHAWAR SR, Haring C, Pan X, Ma J, et al
    Impact of circulating tumor human papillomavirus DNA kinetics on disease outcomes in HPV-associated oropharyngeal cancer.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35291.
    PubMed     Abstract available
    
    
    November 2024
50. JIN ZY, Liu K, Wallar G, Zhou JY, et al
    Environmental tobacco smoking (ETS) and esophageal cancer: A population-based case-control study in Jiangsu Province, China.
    Int J Cancer. 2024 Nov 18. doi: 10.1002/ijc.35254.
    PubMed     Abstract available
    
    
    
51. ABUSAMAK M, Abu-Samak AA, Cai W, Al-Waeli H, et al
    Chronotherapy in head and neck cancer: A systematic review and meta-analysis.
    Int J Cancer. 2024 Nov 7. doi: 10.1002/ijc.35234.
    PubMed     Abstract available
    
    
    
52. RUTKOWSKI TW, Kurczyk A, Drosik-Rutowicz K, Kiprian D, et al
    Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35248.
    PubMed     Abstract available
    
    
    October 2024
53. 
    RETRACTION: A Multiplicity of Anti-Invasive Effects of Farnesyl Transferase Inhibitor SCH66336 in Human Head and Neck Cancer.
    Int J Cancer. 2024 Oct 22. doi: 10.1002/ijc.35230.
    PubMed     Abstract available
    
    
    
54. HSU WL, Tao J, Fu S, Yu KJ, et al
    Kinetics of EBV antibody-based NPC risk scores in Taiwan NPC multiplex families.
    Int J Cancer. 2024;155:1400-1408.
    PubMed     Abstract available
    
    
    September 2024
55. WANG W, Ye L, Li H, Chen W, et al
    A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions.
    Int J Cancer. 2024 Sep 14. doi: 10.1002/ijc.35153.
    PubMed     Abstract available
    
    
    
56. PIRES C, Marques IJ, Saramago A, Moura MM, et al
    Identification of novel candidate predisposing genes in familial nonmedullary thyroid carcinoma implicating DNA damage repair pathways.
    Int J Cancer. 2024 Sep 9. doi: 10.1002/ijc.35159.
    PubMed     Abstract available
    
    
    August 2024
57. JANKE F, Stritzke F, Dvornikovich K, Franke H, et al
    Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy.
    Int J Cancer. 2024 Aug 30. doi: 10.1002/ijc.35152.
    PubMed     Abstract available
    
    
    
58. SHI X, Lu M, Li X, Li J, et al
    The transcriptional landscape and clinico-biological characterization of human endogenous retroviruses in esophageal squamous cell carcinoma.
    Int J Cancer. 2024 Aug 27. doi: 10.1002/ijc.35147.
    PubMed     Abstract available
    
    
    
59. HUANG H, Zhao Y, Deng Y, Zhan Z, et al
    Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study.
    Int J Cancer. 2024 Aug 26. doi: 10.1002/ijc.35139.
    PubMed     Abstract available
    
    
    July 2024
60. WENG Z, Mai Z, Yuan J, Liu Q, et al
    Evolution of genome and immunogenome in esophageal squamous cell carcinomas driven by neoadjuvant chemoradiotherapy.
    Int J Cancer. 2024 Jul 31. doi: 10.1002/ijc.35118.
    PubMed     Abstract available
    
    
    
61. LAURITZEN BB, Gronlund MW, Jakobsen KK, Justesen MM, et al
    Epidemiological trends and survival of oropharyngeal cancer in a high HPV-prevalent area: A Danish population-based study from 2000 to 2020.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35099.
    PubMed     Abstract available
    
    
    June 2024
62. MA L, Wang TM, He YQ, Liao Y, et al
    Multiplex assays reveal anti-EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma.
    Int J Cancer. 2024 Jun 18. doi: 10.1002/ijc.35061.
    PubMed     Abstract available
    
    
    
63. SUN X, Lin X, Yao J, Tian T, et al
    Potential causal links of long-term exposure to PM(2.5) and its chemical components with the risk of nasopharyngeal carcinoma recurrence: A 10-year cohort study in South China.
    Int J Cancer. 2024 Jun 11. doi: 10.1002/ijc.35047.
    PubMed     Abstract available
    
    
    May 2024
64. GUO D, Jin J, Li D, He Y, et al
    Analysis of the incidence and mortality trends of esophageal cancer in cancer registry areas of China and Japan.
    Int J Cancer. 2024 May 21. doi: 10.1002/ijc.35003.
    PubMed     Abstract available
    
    
    April 2024
65. VASILIADOU I, Grose D, Wilson C, Thapa A, et al
    The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34963.
    PubMed     Abstract available
    
    
    
66. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available
    
    
    
67. DI W, Yu J, Zong D, Ge Y, et al
    Effects of ambient temperature, relative humidity and absolute humidity on risk of nasopharyngeal carcinoma in China.
    Int J Cancer. 2024 Apr 10. doi: 10.1002/ijc.34933.
    PubMed     Abstract available
    
    
    
68. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
    Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
    PubMed     Abstract available
    
    
    March 2024
69. CHARTERS E, Cheng K, Dunn M, Heng C, et al
    Restorabite: Phase II trial of jaw stretching exercises using a novel device for patients with trismus following head and neck cancer.
    Int J Cancer. 2024 Mar 31. doi: 10.1002/ijc.34941.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Otorhinolaryngology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum